Soliris 300MG


Indications and Reactions:

Role Indications Reactions
Primary
Paroxysmal Nocturnal Haemoglobinuria 43.2%
Haemolytic Uraemic Syndrome 23.0%
Product Used For Unknown Indication 8.9%
Hypertension 4.6%
Prophylaxis 3.6%
Off Label Use 2.6%
Pain 2.0%
Supplementation Therapy 2.0%
Prophylaxis Against Transplant Rejection 1.6%
Immunosuppression 1.2%
Nausea 1.1%
Anaemia 1.0%
Diabetes Mellitus 0.8%
Immunisation 0.7%
Transplant Rejection 0.7%
Premedication 0.7%
Depression 0.6%
Antibiotic Prophylaxis 0.5%
Anxiety 0.5%
Gastrooesophageal Reflux Disease 0.5%
Pyrexia 10.1%
Death 9.0%
Vomiting 8.7%
Headache 7.6%
Haemoglobin Decreased 6.1%
Nasopharyngitis 6.1%
Platelet Count Decreased 5.3%
Haemolysis 4.3%
Fatigue 4.2%
Pneumonia 4.0%
Transfusion 4.0%
Sepsis 3.9%
Urinary Tract Infection 3.9%
Nausea 3.7%
Pain In Extremity 3.6%
Viral Infection 3.6%
Sinusitis 3.1%
Upper Respiratory Tract Infection 3.1%
White Blood Cell Count Decreased 3.0%
Transplant Rejection 2.8%
Secondary
Paroxysmal Nocturnal Haemoglobinuria 24.9%
Haemolytic Uraemic Syndrome 17.7%
Hypertension 10.3%
Product Used For Unknown Indication 9.6%
Off Label Use 6.5%
Prophylaxis 5.7%
Prophylaxis Against Transplant Rejection 5.5%
Pain 3.3%
Immunosuppression 3.2%
Supplementation Therapy 2.4%
Transplant Rejection 1.9%
Nausea 1.7%
Anaemia 1.4%
Hypersensitivity 0.9%
Infection Prophylaxis 0.9%
Antibiotic Prophylaxis 0.9%
Anxiety 0.9%
Antiphospholipid Syndrome 0.8%
Diabetes Mellitus 0.8%
Oedema 0.8%
Haemolysis 8.3%
Upper Respiratory Tract Infection 8.3%
Viral Infection 8.0%
Sepsis 6.7%
Transplant Rejection 6.7%
Platelet Count Decreased 6.4%
Haemoglobin Decreased 6.1%
Weight Increased 6.1%
Thrombotic Microangiopathy 5.7%
Pyrexia 5.1%
Vomiting 4.5%
Pneumonia 4.1%
Thrombocytopenia 4.1%
Therapeutic Response Decreased 3.8%
Death 3.2%
Septic Shock 2.9%
White Blood Cell Count Decreased 2.9%
Aplastic Anaemia 2.5%
Pain In Extremity 2.5%
Nausea 2.2%

Drug Data